title: [PHARMACOLOGICAL CARDIOPROTECTION DURING REPERFUSION OF ISOLATED HEART].
abstract: OBJECTIVE
  To study the contractile function, the degree of damage and regional myocardial metabolism in the isolated rat heart model subjected to cardioplegic stop and reperfusion under the protection of levosimendan.
  
  
  METHODS
  The study was performed on isolated rat hearts Wistar (group using "Custodiol" vs group using "Custodiol" + "Levosimendan". We assessed the extent of myocardial damage (in terms of markers of myocardial necrosis), the contractile function of the myocardium (coronary flow, heart rate, left ventricular pressure), the dynamics of redox processes during reperfusion with a parallel study of histology of the myocardium.
  
  
  RESULTS
  We found a presence of cardioprotective effect of levosimendan in respect of the isolated heart in the reperfusion period of cardioplegic ischemia. The effect related to reducing the emission of reperfusion enzyme markers of myocardial damage, reducing the severity of pathological changes in the myocardium and reducing the intensity of free radical reactions in the myocardium.
  
  
  CONCLUSIONS
  Cardioprotection with levosimendan reduces the severity of free radical attack the isolated heart, reduces the severity of damage to cardiomyocytes and preserves the contractile activity of the myocardium during reperfusion due to the effect of postconditioning.
authors.forename: E V
authors.initials: EV
authors.lastname: Grigor'ev
authors.forename: Ya G
authors.initials: YG
authors.lastname: Toropova
authors.forename: G P
authors.initials: GP
authors.lastname: Plotnikov
authors.forename: S S
authors.initials: SS
authors.lastname: Krutitskiy
authors.forename: D L
authors.initials: DL
authors.lastname: Shukevich
authors.forename: V V
authors.initials: VV
authors.lastname: Salmin
authors.forename: A S
authors.initials: AS
authors.lastname: Golovkin
mesh_terms: D000818:Animals; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D006324:Heart Arrest, Induced; D006835:Hydrazones / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D066298:In Vitro Techniques; D057775:Ischemic Postconditioning / Q000379:methods*; D009200:Myocardial Contraction / Q000187:drug effects*; D015425:Myocardial Reperfusion; D015428:Myocardial Reperfusion Injury / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D011724:Pyridazines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D017208:Rats, Wistar; D000077464:Simendan
chemical_list: D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D000077464:Simendan